Who are Innate Pharma S.A.'s main suppliers?

Innate Pharma S.A. (IPHA) key suppliers include: AstraZeneca PLC, AstraZeneca PLC, SANOFI, Arcus Biosciences, Inc.. View the full supplier network at chainsifter.com/chain/IPHA.

Who are Innate Pharma S.A.'s major customers?

Innate Pharma S.A. (IPHA) key customers include: Novo Nordisk A/S, Novo Nordisk A/S, Arcus Biosciences, Inc., Sanofi, Sanofi and 5 more. View the full customer network at chainsifter.com/chain/IPHA.

What sector is Innate Pharma S.A. in?

Innate Pharma S.A. (IPHA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Innate Pharma S.A. Supplier List (IPHA): 4 Verified Suppliers

4Suppliers

10Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Innate Pharma S.A. (IPHA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

15Total relationships

1Distinct source URLs

4High confidence

0.735Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Innate Pharma S.A. Suppliers

Ticker	Name	Confidence	Evidence
AZN	AstraZeneca PLC	90%	The Company has significant collaborations with AstraZeneca for the development of monalizumab and IPH5201.
AZN	AstraZeneca PLC	90%	Reciprocal relationship from AZN graph: Reciprocal relationship from IPHA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from IPHA graph: The Company has significant collabora…
SANOFI	SANOFI	90%	The Company also collaborates with Sanofi for the development of IPH62
RCUS	Arcus Biosciences, Inc.	72%	Reciprocal relationship from RCUS graph: Reciprocal relationship from IPHA graph: Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to c…

Innate Pharma S.A. Customers

Ticker	Name	Confidence	Evidence
NVO	Novo Nordisk A/S	72%	Reciprocal relationship from NVO graph: Reciprocal relationship from IPHA graph: ry platform and Antibody Drug Conjugates (ADC). Innate’s portfolio includes its lead proprietary program lacutamab, de…
NVO	Novo Nordisk A/S	72%	ry platform and Antibody Drug Conjugates (ADC). Innate’s portfolio includes its lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymp…
RCUS	Arcus Biosciences, Inc.	72%	Reciprocal relationship from RCUS graph: ny of our investigational products obtain marketing approval, we expect to continue to use third-party manufacturers and may also use Gilead’s internal manufa…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from IPHA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IPHA graph: rovisions of Article L. 225-248 o…
SNYNF	Sanofi	72%	rovisions of Article L. 225-248 of the French Commercial Code, the shareholders decided on May 22, 2025 to pursue the activities of the Company. The likelihood and amount of its future operational lo…
EU-HTA-COORDINATION-GROUP	EU-HTA-COORDINATION-GROUP	62%	MAE payload, is marketed (Enfortumab Vedotin, PADCEV®). Several Nectin-4 targeting ADCs with MMAE are in advanced development, such as candidates from Mabwell (Bulumtatug fuvedotin) and Corbus (CRB-7…
F-27-GROUP	F-27-GROUP	62%	changes in fair value are recognized in equity within the statement of comprehensive income in the period in which they occur. When such assets are derecognized, the cumulative gains and losses previ…
INNATE-PHARMA-INC	INNATE-PHARMA-INC	62%	ry platform and Antibody Drug Conjugates (ADC). Innate’s portfolio includes its lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymp…
PREMISES-INNATE-INC	PREMISES-INNATE-INC	62%	he Company has requested the extension of these two loans repayment for an additional period of five years starting in 2022 and including a one-year grace period. Consequently, the Company has obtain…
RENTSCHLER-FILL-SOLUTIONS-GMBH	RENTSCHLER-FILL-SOLUTIONS-GMBH	62%	o production capabilities and relies on third parties to manufacture its products. This strategy means that the Company does not directly control certain key aspects of its product development, such …

Innate Pharma S.A. Debt Obligations

Instrument	Description	Confidence	Evidence
IPHA-DEBT	Debt stack $26.3M	90%	Market cache reports total debt of $26.3M.

Innate Pharma S.A. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Innate Pharma S.A..

Innate Pharma S.A. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Innate Pharma S.A..

Innate Pharma S.A. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
CALC	CalciMedica, Inc.	100.00	2
ATOS	Atossa Therapeutics, Inc.	100.00	2
ANRO	Alto Neuroscience, Inc.	100.00	2
ALXO	ALX Oncology Holdings Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BLRX	BioLineRx Ltd.	100.00	2
SVA	Sinovac Biotech Ltd.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
CYTK	Cytokinetics, Incorporated	100.00	2
CBIO	Crescent Biopharma, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
CCEP	Coca-Cola Europacific Partners PLC	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
AZN	AstraZeneca PLC	100.00	2	['supplier']
ANL	Adlai Nortye Ltd.	100.00	2
DBVTF	DBV TECHNOLOGIES	100.00	2
CANF	Can-Fite BioPharma Ltd.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2

Innate Pharma S.A. Supply Chain